R&D | May 19, 2026
Teva study exposes major diagnosis gap in Tardive Dyskinesia
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
The agreement could rise to $900 million if key commercial milestones are met
The online platform is designed to go beyond clinical treatment, offering practical tools, lived-experience insights, and peer-informed support intended to reduce isolation and improve day-to-day coping
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Duvakitug was well tolerated and safety was consistent with the induction study
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
Subscribe To Our Newsletter & Stay Updated
